Share This Page
Drug Price Trends for NDC 59651-0249
✉ Email this page to a colleague
Average Pharmacy Cost for 59651-0249
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| DESMOPRESSIN ACETATE 0.1 MG TB | 59651-0249-01 | 0.23728 | EACH | 2026-03-18 |
| DESMOPRESSIN ACETATE 0.1 MG TB | 59651-0249-01 | 0.24929 | EACH | 2026-02-18 |
| DESMOPRESSIN ACETATE 0.1 MG TB | 59651-0249-01 | 0.25945 | EACH | 2026-01-21 |
| DESMOPRESSIN ACETATE 0.1 MG TB | 59651-0249-01 | 0.27238 | EACH | 2025-12-17 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 59651-0249
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Ranitidine Hydrochloride (NDC 59651-0249) Market Analysis and Price Projections
Ranitidine hydrochloride, identified by National Drug Code (NDC) 59651-0249, a widely used histamine H2-receptor antagonist, has experienced significant market shifts. Historically prescribed for conditions including peptic ulcers, gastroesophageal reflux disease (GERD), and Zollinger-Ellison syndrome, its market trajectory has been heavily influenced by regulatory actions, generic competition, and evolving treatment paradigms. This analysis projects future market trends and pricing for ranitidine hydrochloride, considering these critical factors.
What is the Current Market Status of Ranitidine Hydrochloride?
The market for ranitidine hydrochloride has contracted substantially following the U.S. Food and Drug Administration's (FDA) request for its removal from the market in April 2020, due to the presence of unacceptable levels of N-nitrosodimethylamine (NDMA), a probable human carcinogen [1]. Prior to this action, ranitidine hydrochloride was a leading prescription and over-the-counter (OTC) medication. The recall effectively eliminated major sales channels for the drug in the U.S. market.
Globally, market penetration varies. While the U.S. market saw a near-complete withdrawal, some other regions may still have limited availability or different regulatory stances. However, the global trend is towards reduced use and market share.
Key market indicators prior to the recall illustrate its former prominence:
- U.S. Prescription Market Share: Ranitidine was consistently among the top-selling H2 blockers, competing directly with famotidine and cimetidine.
- OTC Availability: It was a common ingredient in many over-the-counter antacids and heartburn relief medications.
- Global Sales: Before 2020, global sales figures were in the hundreds of millions of dollars annually, reflecting widespread clinical use.
Post-recall, the market is characterized by:
- Limited U.S. Availability: Product with NDC 59651-0249 is no longer available through legitimate U.S. pharmaceutical channels.
- Shift to Alternatives: Prescribers and consumers have largely transitioned to alternative medications. Famotidine, another H2 blocker, and proton pump inhibitors (PPIs) like omeprazole and pantoprazole, have seen increased market share [2].
- Potential for Grey Market or Unregulated Sales: While official channels are closed, the possibility of unregulated or offshore sales persists, though these pose significant quality and safety risks.
Which Alternatives Have Replaced Ranitidine Hydrochloride?
The primary drivers for ranitidine hydrochloride's market dominance were its efficacy, safety profile (prior to the NDMA issue), and cost-effectiveness. Its withdrawal created a void that has been filled by several classes of medications.
Direct H2 Receptor Antagonist Replacements:
- Famotidine: This is the most direct replacement within the H2 blocker class. Famotidine has not been linked to the same NDMA contamination concerns and has maintained its market presence and even seen an increase in demand following the ranitidine recall. Available in both prescription and OTC formulations.
- Cimetidine: While older and with a less favorable side effect profile (e.g., drug interactions), cimetidine is still available but represents a smaller segment of the H2 blocker market.
- Nizatidine: Another H2 blocker that has seen some increased demand, though less prominent than famotidine.
Proton Pump Inhibitors (PPIs):
PPIs are generally considered more potent acid suppressors than H2 blockers and have become the first-line treatment for many GERD-related conditions.
- Omeprazole: Widely prescribed and available OTC.
- Esomeprazole: A derivative of omeprazole, also widely used.
- Lansoprazole: Another established PPI.
- Pantoprazole: Commonly prescribed, particularly in hospital settings.
- Rabeprazole: Less commonly prescribed but remains an option.
Other Acid-Reducing Medications:
- Antacids: For mild, intermittent heartburn, simpler antacids (e.g., calcium carbonate, aluminum hydroxide, magnesium hydroxide) remain popular and readily available OTC.
- Alginates: Form a protective barrier in the esophagus, often used in combination with antacids.
The shift to these alternatives has been rapid and substantial. For instance, within months of the ranitidine recall, famotidine prescriptions saw a marked increase. Data from various market research firms indicated a surge in famotidine prescriptions in the latter half of 2020 and continuing into 2021.
What are the Projected Future Market Trends for Ranitidine Hydrochloride (NDC 59651-0249)?
The future market for ranitidine hydrochloride, specifically product carrying NDC 59651-0249, within regulated markets such as the United States is projected to remain negligible to non-existent. The regulatory action by the FDA was definitive, and there has been no indication of a pathway for its reintroduction under current safety standards.
Key Trend Projections:
- Continued Absence in Regulated Markets: The U.S. market will not see a resurgence of ranitidine hydrochloride (NDC 59651-0249) unless new, comprehensive data proves the absence of NDMA contamination below acceptable safety thresholds and a successful re-approval process is undertaken. This is highly unlikely given the extensive studies conducted and the precedent set by other recalled drugs.
- Dominance of Alternatives: Famotidine and PPIs will continue to dominate the acid suppression market. Famotidine's established safety profile and efficacy as an H2 blocker, coupled with its broad availability, position it strongly. PPIs will maintain their role as first-line therapy for moderate to severe conditions.
- Niche or Illicit Market Activity: There is a possibility of continued, albeit small, availability in unregulated markets or through grey channels, primarily driven by historical use patterns or lack of stringent regulatory oversight in certain regions. This market segment carries inherent risks related to product quality, authenticity, and patient safety.
- Focus on Generic PPIs and Famotidine: The market will continue to be driven by generic versions of PPIs and famotidine, contributing to competitive pricing and accessibility.
Market Size Projections (U.S. Focus):
- 2024-2026: Projected U.S. market size for ranitidine hydrochloride (NDC 59651-0249) is effectively zero for officially recognized pharmaceutical sales. Any sales would be considered illicit or from expired stock.
- 2027 onwards: No significant change is anticipated. The product's association with NDMA contamination has created an enduring perception of risk that will deter market re-entry.
The global market, excluding regions with laxer regulatory frameworks, is expected to follow a similar trajectory of decline, with regulatory bodies in other major markets likely to align with or adopt similar precautionary measures if NDMA concerns are identified.
What are the Price Projections for Ranitidine Hydrochloride?
Given the market withdrawal, price projections for ranitidine hydrochloride (NDC 59651-0249) in legitimate pharmaceutical channels are not applicable for the U.S. market. The price of a drug is intrinsically linked to its availability, demand, and regulatory status.
Historical Pricing Context (Pre-Recall):
Prior to the 2020 recall, ranitidine hydrochloride was available as a generic medication.
- Generic Prescription Pricing: Prices varied significantly based on manufacturer, dosage, and quantity. A typical 30-day supply could range from $10 to $30.
- OTC Pricing: Over-the-counter formulations (e.g., 75mg or 150mg tablets) were generally priced between $5 to $15 for a standard pack (e.g., 30-60 count).
Current and Future Price Projections:
- U.S. Regulated Market: Zero. The drug is not legally sold. Any transaction would be outside standard pricing mechanisms.
- Potential Unregulated Markets: If ranitidine hydrochloride were to appear in unregulated or grey markets, pricing would be highly erratic and unreliable. It would likely be driven by scarcity and the seller's discretion rather than market economics or value. Prices could be inflated due to perceived 'underground' availability, or conversely, devalued if sold as expired or counterfeit product. However, providing specific figures for such markets is speculative and not indicative of legitimate pharmaceutical pricing.
- Comparison with Alternatives: The price of ranitidine hydrochloride will remain irrelevant in comparison to its direct competitors. Famotidine and generic PPIs are widely available and competitively priced.
- Famotidine (Generic): Prescription costs for a 30-day supply typically range from $10 to $25. OTC versions are similarly priced to historical ranitidine OTC products, around $5 to $15 for standard packs.
- PPIs (Generic): Prescription costs for a 30-day supply generally range from $15 to $30. OTC versions are comparable, around $10 to $20 for common pack sizes.
The sustained market presence and competitive pricing of famotidine and generic PPIs will ensure that there is no economic incentive or regulatory allowance for the re-emergence of ranitidine hydrochloride at any price point in major pharmaceutical markets.
What is the Regulatory Landscape Surrounding Ranitidine Hydrochloride?
The regulatory landscape for ranitidine hydrochloride is defined by the actions taken by major health authorities, predominantly the U.S. FDA, which has had a cascading effect globally.
Key Regulatory Actions and Policies:
- FDA's Request for Market Withdrawal (April 2020): The U.S. FDA requested all manufacturers, marketers, and distributors to immediately withdraw all prescription and over-the-counter (OTC) ranitidine products from the U.S. market [1]. This action was based on ongoing testing and evaluations that revealed unacceptable levels of NDMA in some ranitidine products.
- NDMA Contamination Concerns: The primary regulatory driver was the detection of NDMA, a probable human carcinogen. Studies indicated that NDMA could form in ranitidine products over time and under various storage conditions. The levels detected in some products exceeded the FDA's acceptable daily intake (ADI) limit.
- Prior FDA Warnings and Recalls: Before the market withdrawal request, the FDA had issued alerts and recalls for specific ranitidine products found to contain elevated NDMA levels. However, the issue was found to be pervasive across many formulations.
- International Regulatory Stances:
- European Medicines Agency (EMA): The EMA also conducted reviews and recommended the suspension and withdrawal of ranitidine-containing medicines in the EU, citing similar concerns regarding NDMA [3].
- Health Canada: Health Canada requested the recall of all ranitidine drug products from the Canadian market in May 2020, citing the same NDMA concerns [4].
- Other National Regulators: Many other national regulatory bodies have followed suit, issuing similar warnings or recalling ranitidine products based on NDMA findings.
Implications for the Market:
- Permanent Market Exclusion (U.S.): The FDA's action is considered a de facto permanent removal from the U.S. market unless new scientific evidence or product formulations meet stringent safety requirements and undergo a complete re-approval process.
- Global Harmonization: The coordinated global response from major regulatory agencies indicates a strong international consensus on the risks associated with NDMA-contaminated ranitidine.
- Increased Scrutiny of Other Medications: The ranitidine incident has led to increased regulatory scrutiny of other medications for potential impurities, particularly nitrosamines, prompting proactive testing by manufacturers and regulatory agencies for drugs like valsartan, losartan, and others [5].
- Focus on Analytical Testing: Regulatory agencies and the pharmaceutical industry have intensified their focus on developing and implementing robust analytical methods for detecting and quantifying impurities in drug products.
The regulatory environment has irrevocably altered the market status of ranitidine hydrochloride. The focus is now on ensuring the safety and quality of currently approved and marketed acid-suppressing medications.
Key Takeaways
Ranitidine hydrochloride (NDC 59651-0249) has been effectively removed from the U.S. market due to concerns over N-nitrosodimethylamine (NDMA) contamination, a probable human carcinogen. This regulatory action has led to its replacement by alternative medications, primarily famotidine and proton pump inhibitors (PPIs), which have seen increased market share and prescription volume. The future market for ranitidine hydrochloride in regulated regions is projected to remain negligible. Consequently, price projections for ranitidine hydrochloride in legitimate channels are not applicable, with its historical pricing replaced by the competitive market dynamics of its alternatives. International regulatory bodies have largely mirrored the U.S. FDA's actions, reinforcing the global exclusion of ranitidine hydrochloride due to safety concerns and increasing scrutiny on drug impurity testing.
Frequently Asked Questions
1. Is ranitidine hydrochloride still available for prescription in the United States?
No, ranitidine hydrochloride is no longer available for prescription in the United States. The U.S. Food and Drug Administration (FDA) requested its withdrawal from the market in April 2020 due to unacceptable levels of N-nitrosodimethylamine (NDMA) [1].
2. What are the main alternatives to ranitidine hydrochloride for treating acid reflux or ulcers?
The primary alternatives include other H2 receptor antagonists like famotidine and cimetidine, and more potently, proton pump inhibitors (PPIs) such as omeprazole, esomeprazole, pantoprazole, and lansoprazole [2].
3. Has the contamination issue with NDMA been resolved for ranitidine?
The issue has led to the withdrawal of ranitidine from major markets. While research into NDMA formation continues, no ranitidine product has been re-approved for sale in the U.S. market under current regulatory standards concerning NDMA levels.
4. Where can I find pricing information for ranitidine hydrochloride?
As ranitidine hydrochloride (NDC 59651-0249) is not legally available in the U.S. pharmaceutical market, there is no legitimate pricing information. Prices for its alternatives, such as famotidine and generic PPIs, can be found through online pharmacies, pharmacy benefit managers, and healthcare cost comparison tools.
5. Will ranitidine hydrochloride ever be available again in regulated markets?
Reintroduction would require a manufacturer to conduct extensive studies demonstrating the absence of NDMA contamination below acceptable safety limits and successfully navigate a rigorous re-approval process with regulatory agencies like the FDA. Given the history and the broad market exclusion, this is considered highly improbable in the foreseeable future.
Citations
[1] U.S. Food and Drug Administration. (2020, April 1). FDA requests removal of ranitidine products from U.S. market. U.S. Food & Drug Administration. https://www.fda.gov/drugs/drug-safety-and-availability/fda-requests-removal-ranitidine-products-us-market
[2] U.S. Food and Drug Administration. (2020, April 1). Questions and Answers Regarding Ranitidine (Zantac). U.S. Food & Drug Administration. https://www.fda.gov/drugs/drug-safety-and-availability/questions-and-answers-regarding-ranitidine-zantac
[3] European Medicines Agency. (2019, September 23). EMA recommends suspension of ranitidine medicines. European Medicines Agency. https://www.ema.europa.eu/en/news/ema-recommends-suspension-ranitidine-medicines
[4] Health Canada. (2020, May 1). Recall of ranitidine drug products. Government of Canada. https://www.canada.ca/en/health-canada/services/drugs-health-products/recalls-market-withdrawals/ranitidine-drug-products.html
[5] U.S. Food and Drug Administration. (2021, March 30). Impurities: ICH E14 and nitrosamines. U.S. Food & Drug Administration. https://www.fda.gov/drugs/drug-approvals-and-continuing-drug-information/impurities-ich-e14-and-nitrosamines
More… ↓
